Does tirzepatide reduce cardiomyocyte death, fibrosis, and hypertrophy in cardiac cells exposed to high glucose concentrations?
Preclinical evidence suggests tirzepatide protects cardiac cells from high glucose-induced damage, providing a mechanistic rationale for its investigation in heart failure clinical trials.
Our findings indicate that TZT has beneficial effects on cardiac cells by positively modulating cardiomyocyte death, fibrosis, and hypertrophy in the presence of high glucose concentrations. This suggests that TZT may reduce the risk of diabetes-related cardiac damage, highlighting its potential as a therapeutic option for heart failure management clinical trials. Our study strongly supports the rationale behind the clinical trials currently underway, the results of which will be further investigated to gain insights into the cardiovascular safety and efficacy of TZT.
Taktaz et al. (Sat,) studied this question.